If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
=== Measurement in body fluids === Fluoxetine and norfluoxetine may be quantitated in blood, plasma, or serum to monitor therapy, confirm a diagnosis of poisoning in hospitalized persons, or assist in a medicolegal death investigation. Blood or plasma fluoxetine concentrations are usually in a range of 50–500 μg/L in persons taking the drug for its antidepressant effects, 900–3000 μg/L in survivors of acute overdosage, and 1000–7000 μg/L in victims of fatal overdosage. Norfluoxetine concentrations are approximately equal to those of the parent drug during chronic therapy but may be substantially less following acute overdosage since it requires at least 1–2 weeks for the metabolite to achieve equilibrium.
Upon learning it was Tetsu, Baachiyo attempts to force himself on the officer before the Dekarangers arrest the alien. Baachiyo is voiced by Motomu Kiyokawa (清川元夢, Kiyokawa Motomu) in his immature form and Taiki Matsuno (松野 太紀, Matsuno Taiki) in his adult form. Spiritian Byoi (スピリト星人ビョーイ, Supirito Seijin Byōi): A gas-based criminal from Planet Spirit who is capable of possessing other beings. He secretly possesses Ban, but is forced out by Hakutaku. Byoi retaliates by piloting a cyclops-themed flight-capable Kaijuki called Hunter Jet (ハンタージェット, Hantā Jetto), but is deleted by Deka Bike Robo. Byoi is voiced by Katsumi Shiono. Beesian Beeling (ビース星人ビーリング, Bīsu Seijin Bīringu): A lizard-themed fighter, from Planet Bees, in Durden's illegal fight club who consumes the illegal steroid Megagesterine and fights Hoji and Tetsu. Beeling is voiced by Yoshimitsu Shimoyama (下山 吉光, Shimoyama Yoshimitsu). Barigean Milibar (バリゲ星人ミリバル, Barige Seijin Miribaru): A aerokinetic cycloptic thief and serial killer from Planet Barige who previously robbed criminals to raise money for orphans before he became reckless. He enlarges himself, but is deleted by Super Dekaranger Robo. During the events of the crossover film Tokusou Sentai Dekaranger vs. Abaranger, Saunaginnan resurrects Milibar, who is subsequently killed by Deka Red, Blue, and Green, and Abare Yellow. Milibar is voiced by Masaru Ōbayashi (大林 勝, Ōbayashi Masaru), who also portrays his human form.
Alongside promotions of general law enforcement and upgrades to courts, the package also provided funding for strengthening the PET's activities in the North Atlantic, and provided new maritime equipment to Greenlandic and Faroese police in response to the crisis. By 19 January 2026, a total of over kr. 88 billion (US$13.7 billion) had been committed to "strengthen defense and security in the Arctic", with kr. 29 billion allocated to acquiring F-35 fighter jets alone, and kr. 27.8 billion for anti-aircraft warfare, according to the Ministry of Defence, and at that point Denmark had sent 200 additional soldiers to Greenland. On the same day, more soldiers together with the Chief of the Royal Danish Army, General Peter Harling Boysen, started arriving in Greenland, and Denmark announced that a "substantial contribution" of its armed forces would be sent there. Also on 19 January, Defence Minister Troels Lund Poulsen and Greenlandic Minister of Foreign Affairs Vivian Motzfeldt met NATO secretary general Rutte and their Nordic Security ministers in Brussels about the situation in Greenland. General Boysen said he is ready to defend Greenland. According to Boysen, the soldiers landed in Kangerlussuaq in western Greenland. On 20 January 2026, Denmark deployed additional troops to Greenland, sending dozens of soldiers and senior military leadership to the Arctic territory to reinforce its presence and participate in ongoing multinational exercises, increasing the Danish Armed Forces' personnel stationed there amid heightened international tensions.
Emanuel Gil-Av (Zimkin) (Hebrew: עמנואל גיל-אב; 7 August 1916 – 24 March 1996) was an Israeli chemist. The main emphasis of his work constituted chiral chromatography for the analytical separation of enantiomers.
Sources: en.wikipedia.org
=== Development === Scandal was renewed for a fifth season on May 7, 2015, by ABC. The series will continue to air at Thursdays in the timeslot 9:00 p.m. E.T. like the previous season, as it was moved to the timeslot to make room for ShondaLand Production Company's new TV series, How to Get Away with Murder. Production began on May 21, 2015, when Rhimes announced on Twitter that the writers were in full swing mapping the fifth season. The remaining fall schedule for ABC was announced on November 16, 2015, where it was announced that Scandal would air nine episodes in the fall with the fall finale to air on November 19, 2015, just like the rest of ABC's primetime lineup "TGIT" Grey's Anatomy and How To Get Away with Murder, which was the same last year. The remaining 12 episodes will air after the winter break, beginning on February 11, 2016, as a result of ABC airing the television miniseries Madoff over two nights on February 3–4, 2016 in the same time-slot as Scandal and Grey's Anatomy. The show was renewed by ABC for a sixth season on March 3, 2016.
=== Apple cultivation === The apple industry is a significant source of employment in Jammu and Kashmir, generating the highest number of jobs. It provides approximately 400-man-days of work per year per hectare of orchards, supporting a workforce of 3.5 million people. Moreover, it contributes approximately 10% to the Gross State Domestic Product (GSDP). In the year 2020–2021, the apple production in Kashmir was reported to be 1,695,000.00 metric tonnes, while in the Jammu Division, it stood at 24,415.69 metric tonnes. The combined apple production for the entire Union Territory of Jammu and Kashmir amounted to 1,719,415.69 metric tonnes. Notably, the Kashmir Valley is the primary contributor to these numbers, accounting for 75% of India's total apple production and exporting around 1.8 million metric tonnes of apples annually.
There are also potential environmental effects from the tools needed for mining these hydrothermal vent ecosystems, including noise pollution and anthropogenic light. Hydrothermal vent system mining would require the use of both submerged mining tools on the seafloor, including remotely operated underwater vehicles (ROVs), as well as surface support vessels on the ocean surface. Inevitably, through the operation of these machines, some level of noise will be created, which presents a problem for hydrothermal vent organisms because, as they are up to 12,000 feet below the surface of the ocean, they experience very little sound. As a result of this, these organisms have evolved to have highly sensitive hearing organs, so if there is a sudden increase in noise, such as that created by mining machinery, there is potential to damage these auditory organs and harm the vent organisms. It is also important to consider that many studies have been able to show that a large percent of benthic organisms communicate using very low-frequency sounds; therefore, increasing ambient noise levels on the seafloor could potentially mask communication between the organisms and alter behavioral patterns. Similar to how deep-sea SMS mining tools create noise pollution, they also create anthropogenic light sources on the seafloor (from mining tools) and the ocean surface (from surface support vessels). Organisms at these hydrothermal vent systems are in the aphotic zone of the ocean and have adapted to very low light conditions.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.